Citius Pharmaceuticals (CTXR) News Today $0.96 +0.03 (+3.23%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 22, 2024 | finance.yahoo.comWhen Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Turn A Profit?July 20, 2024 | finanznachrichten.deEcon Corp Services DBA Investorideas.com: Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)July 18, 2024 | americanbankingnews.comCitius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest UpdateJuly 16, 2024 | marketbeat.comShort Interest in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Drops By 8.5%Citius Pharmaceuticals, Inc. (NASDAQ:CTXR - Get Free Report) saw a significant decline in short interest in June. As of June 30th, there was short interest totalling 14,150,000 shares, a decline of 8.5% from the June 15th total of 15,460,000 shares. Based on an average daily volume of 1,990,000 shares, the days-to-cover ratio is presently 7.1 days.July 10, 2024 | prnewswire.comCitius Pharmaceuticals Details Near-Term Milestones for Late-Stage CandidatesJuly 9, 2024 | marketbeat.comCitius Pharmaceuticals (NASDAQ:CTXR) Stock Price Up 13.7%Citius Pharmaceuticals (NASDAQ:CTXR) Shares Up 13.7%May 31, 2024 | marketbeat.comCitius Pharmaceuticals' (CTXR) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $4.00 price objective on shares of Citius Pharmaceuticals in a research note on Friday.May 31, 2024 | marketbeat.comCitius Pharmaceuticals (NASDAQ:CTXR) Trading Up 4.1%Citius Pharmaceuticals (NASDAQ:CTXR) Trading 4.1% HigherMay 29, 2024 | prnewswire.comCitius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock SolutionMay 21, 2024 | msn.comCitius Pharma's 'Antibiotic Lock' Effective In Patients With Catheter-Associated Bloodstream InfectionsMay 21, 2024 | msn.comCitius gains as late-stage trial for Mino-Lok succeedsMay 21, 2024 | investorplace.comWhy Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today?May 21, 2024 | markets.businessinsider.comCitius Pharma Announce Positive Topline Results For Pivotal Phase 3 Clinical Trial Of Mino-LokMay 21, 2024 | prnewswire.comCitius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock SolutionMay 17, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Autolus Therapeutics (AUTL), Citius Pharmaceuticals (CTXR)May 14, 2024 | investorplace.comCTXR Stock Earnings: Citius Pharma Meets EPS for Q2 2024May 14, 2024 | prnewswire.comCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business UpdateMay 10, 2024 | prnewswire.comCitius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor ConferencesMay 9, 2024 | marketbeat.comCitius Pharmaceuticals (NASDAQ:CTXR) Stock Price Down 3.1%Citius Pharmaceuticals (NASDAQ:CTXR) Trading Down 3.1%April 30, 2024 | prnewswire.comCitius Pharmaceuticals Announces Closing of $15 Million Registered Direct OfferingApril 26, 2024 | prnewswire.comCitius Pharmaceuticals Announces $15 Million Registered Direct OfferingApril 14, 2024 | seekingalpha.comCTXR Citius Pharmaceuticals, Inc.April 11, 2024 | prnewswire.comCitius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell LymphomaApril 9, 2024 | marketbeat.comCitius Pharmaceuticals (NASDAQ:CTXR) Trading Down 3.8%Citius Pharmaceuticals (NASDAQ:CTXR) Shares Down 3.8%April 4, 2024 | prnewswire.comCitius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor ConferenceMarch 20, 2024 | finance.yahoo.comCTXR Apr 2024 7.500 putMarch 20, 2024 | finance.yahoo.comCTXR May 2024 2.500 callMarch 20, 2024 | edition.cnn.comCitius Pharmaceuticals IncMarch 18, 2024 | msn.comCitius Pharmaceuticals receives FDA acceptance of resubmission for its relapsed lymphoma treatmentMarch 18, 2024 | markets.businessinsider.comCitius Pharmaceuticals Announces Acceptance Of BLA Resubmission For LYMPHIR - Quick FactsMarch 18, 2024 | finance.yahoo.comCitius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaMarch 7, 2024 | prnewswire.comCitius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development ProgramMarch 7, 2024 | prnewswire.comCitius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development ProgramFebruary 26, 2024 | finance.yahoo.comCitius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf RegistrationFebruary 26, 2024 | prnewswire.comCitius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf RegistrationFebruary 23, 2024 | finance.yahoo.comCitius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor ConferencesFebruary 14, 2024 | prnewswire.comCitius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business UpdateFebruary 14, 2024 | markets.businessinsider.comBuy Rating for Citius Pharmaceuticals Backed by Resubmission of Lymphir BLA and Potential Orphan Drug ExclusivityFebruary 14, 2024 | finance.yahoo.comCitius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaFebruary 14, 2024 | prnewswire.comCitius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaJanuary 23, 2024 | finance.yahoo.comCitius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of DirectorsJanuary 18, 2024 | marketbeat.comFY2024 Earnings Estimate for Citius Pharmaceuticals, Inc. Issued By HC Wainwright (NASDAQ:CTXR)Citius Pharmaceuticals, Inc. (NASDAQ:CTXR - Free Report) - Equities researchers at HC Wainwright issued their FY2024 EPS estimates for shares of Citius Pharmaceuticals in a research note issued on Tuesday, January 16th. HC Wainwright analyst V. Bernardino forecasts that the company will earn ($0.January 4, 2024 | markets.businessinsider.comStrong Buy Rating for Citius Pharmaceuticals Amid Promising Mino-Lok Progress and Strategic Oncology SpinoutJanuary 2, 2024 | finanznachrichten.deCitius Pharmaceuticals, Inc.: Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage CathetersJanuary 2, 2024 | baystreet.caCitius Ekes out Gains as Trials EndJanuary 2, 2024 | finance.yahoo.comCitius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business UpdateJanuary 2, 2024 | finance.yahoo.comCitius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage CathetersDecember 19, 2023 | marketbeat.comCitius Pharmaceuticals (CTXR) Scheduled to Post Earnings on WednesdayCitius Pharmaceuticals (NASDAQ:CTXR) will be releasing earnings on Wednesday, December 20, Yahoo Finance reports.December 3, 2023 | finance.yahoo.comWe Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth CarefullyNovember 9, 2023 | finance.yahoo.comCitius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023 Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address Charles Payne Demystifies Options (Ad)Did you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Click here to register for free CTXR Media Mentions By Week CTXR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTXR News Sentiment▼0.720.66▲Average Medical News Sentiment CTXR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTXR Articles This Week▼31▲CTXR Articles Average Week Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VTGN News Today MACK News Today DARE News Today TERN News Today NGNE News Today MREO News Today PEPG News Today PRTC News Today ANNX News Today CTNM News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTXR) was last updated on 7/28/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredUrgent alert: open this for a huge profit potentialThis groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
